Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the 56-week EQUIP study were published in Obesity, the peer-reviewed journal of The Obesity Society. The EQUIP study evaluated the efficacy and safety of the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 kg/m2) patients across 91 sites in the US. In addition to average weight loss of 14.4% of initial body weight among those who completed the study at the top dose of Qnexa, severely obese patients had improvements in blood pressure, glucose, triglycerides and cholesterol. The results with Qnexa suggest the potential to effectively treat severely obese patients without surgery.

"Obesity is a serious medical condition that threatens the public health and reduces the quality and length of lives. Currently available treatments are limited and options are needed," said lead investigator Dr. David Allison, director of the Nutrition Obesity Research Center, University of Alabama at Birmingham. "In this population of severely obese patients, those taking Qnexa experienced significant weight loss and reduction in risk factors for many chronic diseases. The results refute a common notion that nonsurgical treatments are not effective for extremely obese persons. The findings are especially relevant to the 14% of the US adult population classified as extremely obese."

Patients in the study had a baseline body mass index of >/= 35 kg/m2, and an average initial weight of 256 pounds. Treatment was well tolerated, with no evidence of serious adverse events induced by treatment.

Specific weight loss results for all patients through 56 weeks as published in Obesity are as follows:

  • Least-squares (LS) mean weight loss for Qnexa patients who completed the EQUIP study was 14.4% and 6.7% with top-dose Qnexa
    '/>"/>

  • SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
    2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
    3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
    4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
    5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
    6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
    7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
    8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
    9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
    10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
    11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... 19, 2014  Today DePuy Synthes Companies of ... plating systems featuring its proprietary variable angle locking ... trajectory to match patient anatomy and fracture pattern ... The systems are being introduced in conjunction with ... and the International Federation of Foot & Ankle ...
    (Date:9/19/2014)... , Sept. 19, 2014 The Parenteral Drug ... harmonize global post-approval changes protocols. The ... the topic expressed by industry participants and regulatory authority ... this month in Washington, DC . ... on hand for the workshop. Attendees indicated openness to ...
    (Date:9/19/2014)... Today, iHealth Lab Inc. announced it has secured ... its first institutional round of funding. The strategic investment ... accelerate growth and innovation, and invest in additional sales ... Ventures will join iHealth,s board of directors, bringing added ... "We are very pleased to have Xiaomi ...
    Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
    ... PARK, N.C. & GENEVA--(BUSINESS WIRE)--Jul 11,2007 ... research and,development program for Plasmin (Human), ... this week at the XXIst International,Society ... in Geneva,Switzerland. The information included new ...
    ... 2007 /PRNewswire-USNewswire/ -- After a,first childhood urinary tract ... infection, and may actually increase,the risk that the ... according to a new study in the July ... Association. , In the first large study of ...
    Cached Medicine Technology:New Information on the Potential of Plasmin Shared at ISTH Congress 2New Information on the Potential of Plasmin Shared at ISTH Congress 3New Information on the Potential of Plasmin Shared at ISTH Congress 4Antibiotics Don't Prevent Future Urinary Tract Infections, May,Cause Resistance in Future Infections 2Antibiotics Don't Prevent Future Urinary Tract Infections, May,Cause Resistance in Future Infections 3
    (Date:9/20/2014)... Lifeinsurancequoteterm.net has released a new blog ... life insurance plan provides for vulnerable family members. ... be a top priority for every provider. It is ... medical examinations and visiting a doctor. , Life ... provide coverage up to $300,000, but only to healthy ...
    (Date:9/20/2014)... 2014 Ticket Down is a ... for her 2015 “Honeymoon Tour.” This well-known ticket exchange ... savings. , In early 2015, fans will have a chance ... across North America. Twenty-one-year-old Ariana Grande will hit the road ... her to 25 cities across the United States and Canada. ...
    (Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), ... new website. The new site provides the latest ... for customers. Here, people can find a lot ... Also, it has recommended some excellent web hosting ... the great web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ...
    (Date:9/20/2014)... (PRWEB) September 20, 2014 Recently, UWDress.com, ... dresses and women’s special occasion outfits, has launched a ... The company’s prom outfits are popular among worldwide clients. ... get wholesale prom dresses on its website. ... for customers from around the world. Great custom made ...
    (Date:9/20/2014)... 2014 RBSEO Services, which has occupied ... has announced it provides an affordable website SEO (Search ... This announcement would benefit those new and old businesses ... cannot afford to pay a big amount for their ... their websites in top search results for their business ...
    Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 3Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:RBSEO Services Announces Affordable Website SEO Service at Only $175 2
    ... Technologies Corp. ( www.harvesttech.com ) announced today ... first thirty (30) patients in the clinical trial of ... advanced thromboangitis obliterans, commonly referred to as Buerger,s Disease. ... University in Chennai India and is designed to evaluate ...
    ... and Only Once-weekly, Self-administered Alternative to Injections for ... 1 Strativa Pharmaceuticals, the proprietary products division ... Companies, Inc. (NYSE: PRX ), today ... Nascobal(R) (Cyanocobalamin, USP) Nasal Spray from QOL Medical ...
    ... /PRNewswire-FirstCall/ -- DaVita Inc. ... nation,s leading providers of kidney care for those ... to launch Lifestyle Management Programs for teammates ... weight management.(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO )DaVita,s Village Vitality, a ...
    ... Corporation (OTC Bulletin Board: CHRX, CHRXU, CHRXW) (the "Company"), ... that it was in technical violation of three financial ... December 31, 2008. Chem Rx continues to ... than as to certain default interest). The covenants ...
    ... and PolyScript(R) Labels Enable Fast and Cost-Effective CustomizationSOUTHFIELD, Mich., ... solutions manufactured specifically to provide equipment with safety warnings ... order to help engineering industries meet the exacting demands ... PreScript (R) and PolyScript ...
    ... released today by the American Health Information Management ... Reporters, Editors, Publications, Washington, D.C. News Bureaus, Washington ... Management Association (AHIMA) WHAT: 2009 ICD-10 ... April 16-17, 2009 WHERE: ...
    Cached Medicine News:Health News:Harvest Technologies Announces Interim Study Results From Critical Limb Ischemia Trial in Chennai India 2Health News:Harvest Technologies Announces Interim Study Results From Critical Limb Ischemia Trial in Chennai India 3Health News:Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical 2Health News:Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical 3Health News:Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical 4Health News:DaVita's Customized Lifestyle Management Programs Assist Employees to Meet Their Lifestyle Goals 2Health News:Chem Rx Corporation in Technical Violation of Three Financial Debt Covenants 2Health News:Chem Rx Corporation in Technical Violation of Three Financial Debt Covenants 3Health News:Schreiner ProTech Introduces Intelligent Marking Solutions Achieving Process and Cost Optimizations 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: